Neurosteroids in child and adolescent psychopathology

European Neuropsychopharmacology

Volumn 17, Issue 3, 2007, Pages 157-164

  Golubchik, Pavel ^a,b   Lewis, Matthew ^a,c,d   Maayan, Rachel ^d   Sever, Jonathan ^a,b   Strous, Rael ^b,e   Weizman, Abraham ^a,b,d  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MINISTRY OF HEALTH   (Israel)

^d RABIN MEDICAL CENTER   (Israel)

^e BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

Author keywords

Adolescents; Neurodevelopment; Neurosteroid; Psychopathology; Treatment

Indexed keywords

NEUROSTEROID;

ADOLESCENT; AGGRESSION; ANOREXIA NERVOSA; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; CONDUCT DISORDER; DEPRESSION; EATING DISORDER; HUMAN; MENTAL DISEASE; NERVE CELL DIFFERENTIATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OPPOSITIONAL DEFIANT DISORDER; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ADOLESCENT; AGGRESSION; ANOREXIA NERVOSA; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; CHILD; DEPRESSIVE DISORDER; HUMANS; MENTAL DISORDERS; NEUROTRANSMITTER AGENTS; SCHIZOPHRENIA; STEROIDS;

EID: 33751192283     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.08.003     Document Type: Review

References (96)

1. Anderson G.M. Monoamines in autism: an update of neurochemical research on a pervasive developmental disorder. Med. Biol. 65 (1987) 67-74
2. Bastianetto S., Ramassamy C., Poirier J., and Quirion R. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Mol. Brain Res. 66 (1999) 35-41
3. Baulieu E.E. Steroid hormones in the brain: several mechanisms. In: Fuxe K., Gustafson J.A., and Wetterberg L. (Eds). Steroid Hormone Regulation of the Brain (1981), Pergamon, Elmsford, NY 3-14
4. Baulieu E.E., and Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J. Endocrinol. 150 (1996) S221-S239
5. Baulieu E., and Schumacher M. Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination. Steroids 65 (2000) 605-612
6. Bergeron R., de Montigny C., and Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J. Neurosci. 16 (1996) 1193-1202
7. Bloch M., Rubinow D.R., Adams L.F., Danaceau M.A., and Schmidt P.J. Dehydroepiandrosterone treatment of midlife dysthymia. Biol. Psychiatry 45 (1999) 1531-1532
8. Bologa L., Sharma J., and Roberts E. Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures. J. Neurosci. Res. 17 (1987) 225-234
9. Brambilla F., Biggio G., Pisu M.G., Bellodi L., Perna G., Bogdanovich-Djukic V., Purdy R.H., and Serra M. Neurosteroid secretion in panic disorder. Psychiatry Res. 118 (2003) 107-116
10. Buitelaar J.K., and Willemsen-Swinkels S.H. Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy. Paediatr. Drugs 2 (2000) 67-81
11. Buydens-Branchey L., and Branchey M. Cocaine addicts with conduct disorder are typified by decreased cortisol responsivity and high plasma levels of DHEA-S. Neuropsychobiology 50 (2004) 161-166
12. Carlsson M.L. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate-serotonin interactions for pharmacotherapy. J. Neural Transm. 105 (1998) 525-535
13. Chan J.R., Phillips II L.J., and Glaser M. Glucocorticoids and progestins signal the initiation and enhance the rate of myelin formation. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 10459-10464
14. Chugani D.C. Role of altered brain serotonin mechanisms in autism. Mol. Psychiatry 7 Suppl 2 (2002) S16-S17
15. Cohen B.I. GABA-transaminase, the liver and infantile autism. Med. Hypotheses 57 (2001) 673-674
16. Compagnone N.A., and Mellon S.H. Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4678-4683
17. Constantino J.N., Grosz D., Saenger P., Chandler D.W., Nandi R., and Earls F.J. Testosterone and aggression in children. J. Am. Acad. Child Adolesc. Psych. 32 (1993) 1212-1222
18. Corpechot C., Robel P., Axelson M., Sjovall J., and Baulieu E.E. Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 4704-4707
19. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 3 (1996) 241-253
20. Demirgoren S., Majewska M.D., Spivak C.E., and London E.D. Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABAA receptor. Neuroscience 45 (1991) 127-135
21. Devesa J., Perz-Fernandes R., Bokser L., Gaudiero G.J., Lima L., and Casanueva F.F. Adrenal androgen secretion and dopaminergic activity in anorexia nervosa. Horm. Metab. Res. 20 (1987) 57-60
22. Dhossche D., Applegate H., Abraham A., Maertens P., Bland L., Bencsath A., and Martinez J. Elevated plasma gamma-aminobutyric acid (GABA) levels in autistic youngsters: stimulus for a GABA hypothesis of autism. Med. Sci. Monit. 8 (2002) 1-6
23. Dmitrieva T.N., Oades R.D., Hauffa B.P., and Eggers C. Dehydroepiandrosterone sulphate and corticotropin levels are high in young male patients with conduct disorder: comparison for growth factors, thyroid and gonadal hormones. Neuropsychobiology 43 (2001) 134-140
24. Engel S.R., and Grant K.A. Neurosteroids and behavior. Int. Rev. Neurobiol. 46 (2001) 321-348
25. Fadalti M., Petraglia F., Luisi S., Bernardi F., Casarosa E., Ferrari E., Luisi M., Saggese G., Genazzani A.R., and Bernasconi S. Changes of serum allopregnanolone levels in the first 2 years of life and during pubertal development. Pediatr. Res. 46 (1999) 323-327
26. Fish E.W., Faccidomo S., DeBolt J.F., and Miczek K.A. Alcohol, allopregnanolone and aggression in mice. Psychopharmacology 153 (2001) 391-399
27. Flood J.F., and Roberts E. Dehydroepiandrosterone sulfate improves memory in aging mice. Brain Res. 448 (1988) 178-181
28. Friess E., Schiffelholz T., Steckler T., and Steiger A. Dehydroepiandrosterone-a neurosteroid. Eur. J. Clin. Investig. 30 Suppl 3 (2000) 46-50
29. Galderisi S., Mucci A., Monteleone P., Sorrentino D., Piegari G., and Maj M. Neurocognitive functioning in subjects with eating disorders: the influence of neuroactive steroids. Biol. Psychiatry 53 (2003) 921-927
30. Gizerian S.S., Morrow A.L., Lieberman J.A., and Grobin A.C. Neonatal neurosteroid administration alters parvalbumin expression and neuron number in medial dorsal thalamus of adult rats. Brain Res. 1012 (2004) 66-74
31. Gizerian S.S., Moy S.S., Lieberman J.A., and Grobin A.C. Neonatal neurosteroid administration results in development-specific alterations in prepulse inhibition and locomotor activity: neurosteroids alter prepulse inhibition and locomotor activity. Psychopharmacology 186 (2006) 334-342
32. Goodyer I.M., Herbert J., Altman P.M., Pearson J., Secher S.M., and Shiers H.M. Adrenal secretion during major depression in 8-16-year-olds: I. Altered diurnal rhythms in salivary cortisol and dehydroepiamdrosterone (DHEA) presentation. Psychol. Med. 26 (1996) 245-256
33. Goodyer I.M., Herbert J., Tamplin A., and Altham P.M. Recent life events, cortisol, dehydroepiandrosterone and the onset of major depression in high-risk adolescents. Br. J. Psychiatry 177 (2000) 499-504
34. Goodyer I.M., Park R.J., Netherton C.M., and Herbert J. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. Br. J. Psychiatry 179 (2001) 243-249
35. Goodyer I.M., Herbert J., and Tamplin A. Psychoendocrine antecedents of persistent first-episode major depression in adolescents: a community-based longitudinal enquiry. Psychol. Med. 33 (2003) 601-610
36. Gordon C.M., Goodman E., Emans S.J., Grace E., Becker K.A., Rosen C.J., Gundberg C.M., and LeBoff M.S. Physiologic regulation of bone turnover in adolescent girls with anorexia nervosa. J. Pediatr. 141 (2000) 64-70
37. Gothelf D., Soreni N., Nachman R.P., Tyano S., Hiss Y., Reiner O., and Weizman A. Evidence for the involvement of the hippocampus in the pathophysiology of schizophrenia. Eur. Neuropsychopharmacol. 10 (2000) 389-395
38. Grobin A.C., Gizerian S., Lieberman J.A., and Morrow A.L. Perinatal allopregnanolone influences prefrontal cortex structure, connectivity and behavior in adult rats. Neuroscience 138 (2006) 809-819
39. Harris D.S., Wolkowitz O.M., and Reus V.I. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J. Biol. Psychiatry 2 (2001) 99-102
40. Haug M., Spetz J.F., Schlegel M.L., and Robel P. Dehydroepiandrosterone inhibits aggressive behavior in castrated male mice. Comptes Rendus Seances Acad. Sci. 296 (1983) 975-977
41. Herbert J. Neurosteroids, brain damage, and mental illness. Exp. Gerontol. 33 (1998) 713-727 (Review)
42. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
43. Kaur G., and Kulkarni S.K. Subchronic studies on modulation of feeding behavior and body weight by neurosteroids in femail mice. Methods Find. Exp. Clin. Pharmacol. 23 (2001) 115-119
44. Kimonides V.G., Khatibi N.H., Svendsen C.N., Sofroniew M.V., and Herbert J. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 1852-1857
45. Koenig H.L., Schumacher M., Ferzaz B., Thi A.N., Ressouches A., Guennoun R., Jung-Testas I., Robel P., Akwa Y., and Baulieu E.E. Progesterone synthesis and myelin formation by Schwann cells. Science 268 (1995) 1500-1503
46. Kroboth P.D., Salek F.S., Pittenger A.L., Fabian T.J., and Frye R.F. DHEA and DHEA-S: a review. J. Clin. Pharmacol. 39 (1999) 327-348
47. Labrie F., Belander A., and Cusan L. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab. 82 (1997) 2396-2402
48. Lahti A.C., Koffel B., LaPorte D., and Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychol. Pharmacol. 13 (1995) 9-19
49. Lipska B.K. A neurodevelopmental model of schizophrenia: neonatal disconnection of hippocampus. Neurotox. Res. 4 (2002) 469-475
50. Lipska B.K. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J. Psychiatry Neurosci. 29 (2004) 282-286
51. Maayan R., Yagorowski Y., Grupper D., Weiss M., Shtaif B., Kaoud M.A., and Weizman A. Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biol. Psychiatry 48 (2000) 693-701
52. Maayan R., Yoran-Hegesh R., Strous R., Nechmad A., Averbuch E., Weizman A., and Spivak B. Three-month treatment course of methylphenidate increases plasma levels of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S) in attention deficit hyperactivity disotder. Neuropsychobiology 48 (2003) 111-115
53. Majewska M.D., Demirgoren S., Spivak C.E., and London E.D. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res. 526 (1990) 143-146
54. Maki P., Veijola J., Jones P.B., Murray G.K., Koponen H., Tienari P., Miettunen J., Tanskanen P., Wahlberg K.E., Koskinen J., Lauronen E., and Isohanni M. Predictors of schizophrenia-a review. Br. Med. Bull. 73 (2005) 1-15
55. Mao X., and Barger S.W. Neuroprotection by dehydroepiandrosterone-sulfate: role of an NFkappaB-like factor. NeuroReport 9 (1998) 59-63
56. Marenco S., and Weinberger D.R. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev. Psychopathol. 12 (2000) 501-527
57. Marx C.E., Jarskog L.F., Lauder J.M., Gilmore J.H., Lieberman J.A., and Morrow A.L. Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia. Brain Res. 871 (2000) 104-112
58. Marx C.E., Stevens R.D., Shampine L.J., Uzunova V., Trost W.T., Butterfield M.I., Massing M.W., Hamer R.M., Morrow A.L., and Lieberman J.A. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology 31 (2006) 1249-1263
59. 1 receptor: pharmacological evidence and therapeutic opportunities. Jpn. J. Pharmacol. 81 (1999) 125-155
60. A receptors, and escalated aggressive behavior. Horm. Behav. 44 (2003) 242-257
61. Monnet F.P., Mahe V., Robel P., and Baulieu E.E. Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-d-aspartate in the rat hippocampus. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 3774-3778
62. Monteleon P., Luisi M., Colurcio B., Cassarosa E., Loime R., Genazzani A.R., and Maj M. Plasma levels of neuroactive steroids are increased in untreated women with anorexia nervosa or bulimia nervosa. Psychosom. Med. 63 (2001) 52-68
63. Nechmad A., Maayan R., Ramadan E., Morad O., Poyurovsky M., and Weizman A. Clozapine decreases rat brain dehydroepiandrosterone and dehydroepiandrosterone sulfate levels. Eur. Neuropsychopharmacol. 13 (2003) 29-31
64. Nicolas L.B., Pinoteau W., Papot S., Routier S., Guillaumet G., and Mortaud S. Aggressive behavior induced by the sulfatase inhibitor COUMATE and by DHEA-S in CBA/H mice. Brain Res. 922 (2001) 216-222
65. Paul S.M., and Purdy R.H. Neuroactive steroids. FASEB J. 6 (1992) 2311-2322
66. Pinna G., Costa E., and Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology 86 (2006) 362-372
67. Rasmusson A.M., Vythilingam M., and Morgan III C.A. The neuroendocrinology of post-traumatic stress disorder: new directions. CNS Spectr. 8 (2003) 651-667
68. Ritsner M., Maayan R., Gibel A., Strous R.D., Modai I., and Weizman A. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur. Neuropsychopharmacol. 14 (2004) 267-273
69. Ritsner M., Gibel A., Maayan R., Ratner Y., Ram E., Biadsy H., Modai I., and Weizman A. Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology 30 (2005) 1913-1922
70. Ritsner M., Gibel A., Ram E., Maayan R., and Weizman A. Alterations in DHEA metabolism in schizophrenia: two-month case-control study. Eur. Neuropsychopharmacol. 16 (2006) 137-146
71. Roberts E., Bologa L., Flood J.F., and Smith G.E. Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice. Brain Res. 406 (1987) 357-362
72. Rupprecht R., di Michele F., Hermann B., Strohle A., Lancel M., Romeo E., and Holsboer F. Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res. Rev. 37 (2001) 59-67
73. Sakamoto H., Ukena K., and Tsutsui K. Effects of progesterone synthesized de novo in the developing Purkinje cell on its dendritic growth and synaptogenesis. J. Neurosci. 21 (2001) 6221-6232
74. Schlegel M.L., Spetz J.F., Robel P., and Haug M. Studies on the affects of dehydroepiandrosterone and its metabolites on attack by castrated mice on lactating intruders. Physiol. Behav. 34 (1985) 867-870
75. Schmidt P.J., Daly R.C., Bloch M., Smith M.J., Danaceau M.A., St Clair L.S., Murphy J.H., Haq N., and Rubinow D.R. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch. Gen. Psychiatry 62 (2005) 154-162
76. Schumacher M., Robel P., and Baulieu E.E. Development and regeneration of the nervous system: a role for neurosteroids. Dev. Neurosci. 18 (1996) 6-21
77. Schumacher M., Weill-Engerer S., Liere P., Robert F., Franklin R.J., Garcia-Segura L.M., Lambert J.J., Mayo W., Melcangi R.C., Parducz A., Suter U., Carelli C., Baulieu E.E., and Akwa Y. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog. Neurobiol. 71 (2003) 3-29
78. Shirayama Y., Hashimoto K., Suzuki Y., and Higuchi T. Correlation of plasma neurosteroid level to the severity of negative symptoms in male patients with schizophrenia. Schizophr. Res. 58 (2002) 69-74
79. Spivak B., Maayan R., Kotler M., Mester R., Gil-Ad I., Shtaif B., and Weizman A. Elevated circulatory level of GABA(A)-antagonistic neurosteroids inpatients with combat-related post-traumatic stress disorder. Psychol. Med. 30 (2000) 1227-1231
80. Stein D., Maayan R., Ram A., Loewenthal R., Achiron A., Modan-Moses D., Feigin M., Weizman A., and Valevski A. Circulatory neurosteroid levels in underweight female adolescent anorexia nervosa inpatients and following weight restoration. Eur. Neuropsychopharmacol. 15 (2005) 647-653
81. Strous R.D., Spivak B., Yoran-Hegesh R., Maayan R., Averbuch E., Kotler M., Mester R., and Weizman A. Analysis of neurosteroid levels in attention deficit hyperactivity disorder. Int. J. Neuropsychopharmacol. 4 (2001) 259-264
82. Strous R.D., Maayan R., Lapidus R., Stryjer R., Lustig M., Kotler M., and Weizman A. Dehydroepiandrosterone augmentation in the management of negative, depressive and anxiety symptoms in schizophrenia. Arch. Gen. Psychiatry 60 (2003) 133-141
83. Strous R.D., Golubchik P., Maayan R., Mozes T., Tuati-Werner D., Weizman A., and Spivak B. Lowered DHEA-S plasma levels in adult individuals with autistic disorder. Eur. Neuropsychopharmacol. 15 (2003) 305-309
84. Strous R.D., MGrobin A.C., Gizerian S., Lieberman J.A., and Morrow A.L. Perinatal allopregnanolone influences prefrontal cortex structure, connectivity and behavior in adult rats. Neuroscience 138 (2006) 809-819
85. Tagawa N., Hidaka Y., Takano T., Shimoaka Y., Kobayashi Y., and Amino N. Serum concentrations of dehydroepiandrosterone and dehydroepiandrosterone sulfata and their relation to cytokine production during and after normal pregnancy. Clin. Chim. Acta 340 (2004) 187-193
86. Tordjman S., Anderson G.M., McBride P.A., Hertzig M.E., Snow M.E., Hall L.M., Ferrari P., and Cohen D.J. Plasma androgens in autism. J. Autism Dev. Disord. 25 (1995) 295-304
87. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., and Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3239-3244
88. Uzunova V., Sampson L., and Uzunov D.P. Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action. Psychopharmacology 186 (2006) 351-361
89. Van Goozen S.H.M., Matthys W., Cohen-Kettenis P.T., Thijssen J.H.H., and van Engeland H. Adrenal androgens and aggression in conduct disorder prepubertal boys and normal controls. Biol. Psychiatry 43 (1998) 156-158
90. Van Goozen S.H., van den Ban E., Matthys W., Cohen-Kettenis P.T., Thijssen J.H., and van Engeland H. Increased adrenal androgen functioning in children with oppositional defiant disorder: a comparison with psychiatric and normal controls. J. Am. Acad. Child Adolesc. Psych. 39 (2000) 1446-1451
91. Weaver Jr. C.E., Wu F.S., Gibbs T.T., and Farb D.H. Pregnenolone sulfate exacerbates NMDA-induced death of hippocampal neurons. Brain Res. 803 (1998) 129-136
92. Weinberger D.R., and Lipska B.K. Cortical maldevelopment, antipsychotic drugs, and schizophrenia: in search of common ground. Schizophr. Res. 16 (1995) 87-110
93. Winterer J., Gwirtsman H.E., George D.T., Kaye W.H., Lotiaux D.L., and Cuter G.B. Adrenocorticotropin-stimulated adrenal androgen secretion in anorexia nervosa: impaired secretion at low weight with normalization after long term recovery. J. Clin. Endocrinol. Metab. 61 (1985) 693-697
94. Wolkowitz O.M., and Reus V.I. Neurotransmitters, neurosteroids and neurotrophins: new models of the pathophysiology and treatment of depression. World J. Biol. Psychiatry 4 (2003) 98-102
95. Wolkowitz O.M., Reus V.I., Keebler A., Nelson N., Friedland M., Brizendine L., and Roberts E. Double-blind treatment of major depression with dehydroepiandrosterone. Am. J. Psychiatry 156 (1999) 646-649
96. Zumoff B., Walsh B.T., Katz J.L., Levin J., Rosenfeld R.S., Kream J., and Weiner H. Subnormal plasma dehydroisoandrosterone to cortisol ratio in anorexia nervosa: a second hormonal parameter of ontogenic regression. J. Clin. Endocrinol. Metab. 56 (1983) 668-672